Although many compounds look similar to this compound(136725-55-8)Quality Control of (R)-(-)-3-Fluoropyrrolidine Hydrochloride, numerous studies have shown that this compound(SMILES:Cl.F[C@@H]1CCNC1), has unique advantages. If you want to know more about similar compounds, you can read my other articles.
Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Journal of Medicinal Chemistry called PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer′s Disease and Other Tauopathies, Author is Kroth, Heiko; Oden, Felix; Molette, Jerome; Schieferstein, Hanno; Gabellieri, Emanuele; Mueller, Andre; Berndt, Mathias; Sreenivasachary, Nampally; Serra, Andreia Monica; Capotosti, Francesca; Schmitt-Willich, Heribert; Hickman, David; Pfeifer, Andrea; Dinkelborg, Ludger; Stephens, Andrew, which mentions a compound: 136725-55-8, SMILESS is Cl.F[C@@H]1CCNC1, Molecular C4H9ClFN, Quality Control of (R)-(-)-3-Fluoropyrrolidine Hydrochloride.
The first candidate PI-2014 was tested in healthy controls and subjects with Alzheimer′s disease (AD). As PI-2014 displayed off-target binding to monoamine oxidase A (MAO-A), a new lead with improved binding to Tau and decreased MAO-A binding was required. For compound optimization, Tau binding assays based on both human AD brain homogenate and Tau-paired helical filaments were employed. Furthermore, two MAO-A screening assays based on (1) human-recombinant MAO-A and (2) displacement of 2-fluoro-ethyl-harmine from mouse brain homogenate were employed. Removing the N-Me group from the tricyclic core resulted in compounds displaying improved Tau binding. For the final round of optimization, the cyclic amine substituents were replaced by pyridine derivatives PI-2620 (2-(2-fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c′]dipyridine) emerged as a best candidate displaying high Tau binding, low MAO-A binding, high brain uptake, and fast and complete brain washout. Furthermore, PI-2620 showed Tau binding on brain sections from corticobasal degeneration, progressive supranuclear palsy, and Pick′s disease.
Although many compounds look similar to this compound(136725-55-8)Quality Control of (R)-(-)-3-Fluoropyrrolidine Hydrochloride, numerous studies have shown that this compound(SMILES:Cl.F[C@@H]1CCNC1), has unique advantages. If you want to know more about similar compounds, you can read my other articles.
Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem